EFS or PFS, Stratified by I-PET, for Studies of DLBCL Without Risk-Adapted Therapy
| 2-y PFS/EFS | 3-y PFS/EFS | |||||||||
| Author | Type of study | I-PET after n cycles (cycles %) | No. of subjects | Median follow-up (mo) | Study cohort PFS (y) | I-PET–positive (n) | I-PET–negative survival | I-PET–positive survival | I-PET–negative survival | I-PET–positive survival |
| Zinzani et al. (26) | Retrospective | 3 cycles (or mid-therapy*) | 91 | 50 m | 38% | 94%† | 45%† | |||
| Cashen et al. (25) | Prospective | 2–3 cycles (2 in 94%) | 50 | 34 m | 74% (2 y) | 48% | 85% (72%–100%)‡ | 63% (46%–85%)‡ | ||
| Yoo et al. (24) | Retrospective | 2–4 cycles (2–3 in 57%) | 155 | 20 m | 77% (3 y) | 36% | 84% | 66% | ||
| Pregno et al. (23) | Prospective | 2–4 cycles (2–3 in 76%) | 88 | 26 m | 77% (2 y) | 28% | 85% | 72% | ||
| Safar et al. (22) | Prospective | 2 cycles | 112 | 38 m | 84% (3 y) | 37% | 84% (75%–94%)‡ | 47% (32%–62%)‡ | ||
| IAEA Lymphoma Group | Prospective | 2–4 cycles(2–3 in 99%) | 327 | 35 m | 79% (2 y) | 36% | 90 (85%–93%)‡ | 58% (48%–66%)‡ | 86% (79%–90%)‡ | 45% (34%–55%)‡ |
↵* Treatments included MACOP-B, R-VNCOP-B, R-CHOP21.
↵† 2-y EFS by personal communication from Pier Luigi Zinzani (associated member of IAEA Lymphoma Study Group).
↵‡ CIs are shown for studies when they were included in cited report.
Only studies using visual reporting criteria are included in this comparison. Studies primarily assessing after 4 cycles of chemotherapy were not included. Outcome, PFS, or EFS, as reported by each study.